Related Experiment Videos
Peptide vaccines against hepatitis B virus: from animal model to human studies
1Clinic of Rheumatology and Clinical Immunology/Allergology, University Hospital, Inselspital Bern, 3010, Bern, Switzerland.
Insights
Therapeutic vaccines using immunogenic peptides can boost cellular immunity to help eliminate the hepatitis B virus (HBV). These findings advance the development of effective treatments for chronic hepatitis B infection.
Area of Science:
- Hepatology
- Immunology
- Vaccinology
Background:
- Chronic hepatitis B virus (HBV) infection affects 400 million people globally, leading to severe liver diseases like cirrhosis and cancer.
- Current preventive vaccines are effective but therapeutic options for chronic infections remain limited.
- Cell-mediated immunity is critical for viral clearance, making it a key target for new treatments.
Purpose of the Study:
- To review pre-clinical and clinical data on immunogenic peptide-based vaccines for chronic hepatitis B.
- To assess the potential of these vaccines in selectively boosting cellular immune responses.
- To evaluate their role in developing a therapeutic vaccine against chronic HBV.
Main Methods:
- Summary of pre-clinical studies in animal models.
- Analysis of clinical trial data in humans.
- Evaluation of immunogenicity and immune response profiles.
Main Results:
- Peptide-based vaccines demonstrated the ability to generate significant cellular immune responses in both animal models and human subjects.
- These responses were targeted towards enhancing cell-mediated immunity relevant to viral elimination.
- The approach showed promise in modulating the immune system against persistent HBV infection.
Conclusions:
- Immunogenic peptide vaccines represent a promising strategy for therapeutic intervention in chronic hepatitis B.
- These vaccines can effectively stimulate cellular immunity, a crucial factor in controlling HBV.
- Further development is warranted to establish these as viable therapeutic options for millions affected by chronic HBV.
Abstract:
An estimated 400 million people are chronically infected with the hepatitis B virus (HBV). Chronic viral hepatitis infection incurs serious sequelae such as liver cirrhosis and hepatocellular carcinoma. Prevention and treatment, thus, represent an important target for public health. Preventive vaccines using HBsAg alone or combined with other antigens allow for the generation of neutralizing antibodies which effectively prevent infection in immunocompetent individuals. Cell-mediated immunological mechanisms are thought to be crucial in determining viral persistence or viral elimination. Therapeutic approaches aiming to shift cellular immunity towards viral elimination have been on the research agenda for many years. This paper summarizes pre-clinical and clinical results obtained with the use of immunogenic peptides formulated as vaccines to selectively boost cellular immune responses. Such vaccines are capable of generating cellular immune responses in animal models as well as in humans and represent an important step towards the development of a therapeutic vaccine against chronic hepatitis.